INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …

Global containment of COVID-19 still requires accessible and affordable vaccines for low-and
middle-income countries (LMICs). 1 Recently approved vaccines provide needed …

B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most
resistant to antibody neutralization. We demonstrate how the dose and number of …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529)
variant has proven to be highly transmissible and has outcompeted the Delta …

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of
vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (…

Second-generation COVID-19 vaccines could contribute to establish protective immunity
against SARS-CoV-2 and its emerging variants. We developed COH04S1, a synthetic …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have
emerged and may pose a threat to both the efficacy of vaccines based on the original WA1/…

mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there
are limited data on the impact of durability of immune responses on protection. Here, we …

Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine efficacy
through multiple immune mechanisms including neutralizing antibody evasion. We …

Global containment of COVID-19 still requires accessible and affordable vaccines for low-
and middle-income countries (LMICs). Recently approved vaccines provide needed …